Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Impact of metformin on HBV replication: No evidence of suppression in vitro

Hawkins C. et al, (2025), Journal of Clinical Virology, 177, 105781 - 105781

Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families

Jemutai J. et al, (2025), The Lancet Gastroenterology & Hepatology, 10, 100 - 103

Pathogens don't respect politicians: US federal disruption poses a new threat to global public health

Wang S. et al, (2025), The Lancet Gastroenterology & Hepatology

Reply to: “Understanding virologic heterogeneity in chronic hepatitis B treatment”

Matthews PC. et al, (2025), JHEP Reports, 7, 101280 - 101280

Knowledge, attitudes and practices to hepatitis B among South African primary healthcare staff

Mashilo A. et al, (2025), African Journal of Primary Health Care & Family Medicine, 17

Detecting changes in population trends in infection surveillance using community SARS-CoV-2 prevalence as an exemplar

Pritchard E. et al, (2024), American Journal of Epidemiology, 193, 1848 - 1860

Corrigendum to A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.: Journal of Clinical Virology 174 (2024) 105711.

Lumley SF. et al, (2024), Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 174

Load More